세계의 바이오시밀러 시장 : 약제 클래스별(단클론항체(아달리무맙, 인플릭시맙, 리툭시맙, 트루스투주맙, 인슐린, 에리스로포이에틴, 항응고제, rhGH), 적응증별, 지역별 예측(-2028년)

Biosimilars Market by Drug Class (Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Trastuzumab), Insulin, Erythropoietin, Anticoagulants. rhGH), Indication, Region - Global Forecast to 2028

US $ 4,950 ￦ 7,162,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,621,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,792,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 14,469,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 바이오시밀러 시장 규모는 2023년 294억 달러에서 2028년 669억 달러로 예측 기간 동안 17.8%의 CAGR로 성장할 것으로 예상됩니다. 규제 당국의 승인, 유리한 상환 정책, 비용 효율적인 바이오시밀러에 대한 수요 증가 등의 요인이 시장 성장을 촉진하고 있습니다.

"단클론항체 제품 부문은 예측 기간 동안 약제 클래스별로 가장 높은 성장률을 달성했다"

2022년 단클론항체 제품 부문은 바이오시밀러 시장에서 가장 큰 점유율을 차지했는데, 이는 주로 바이오시밀러 단클론항체의 가격이 기준약에 비해 저렴하고 암, 자가면역질환 및 골다공증 치료에 대한 연구소의 채택이 증가했기 때문입니다. 급성장 부문의 성장은 전 세계 암 및 만성질환의 발병률 증가에 기인합니다. 호환 가능한 인슐린 제제의 승인 확대는 시장에 긍정적인 영향을 미칠 것으로 보입니다.

"적응증별로는 2022년 암 영역이 가장 큰 점유율을 차지할 것"

암 치료제와 성장호르몬에 대한 수요 증가는 다양한 지역에서 바이오시밀러 시장의 성장을 견인하고 있습니다.

"아시아태평양이 더 빠른 속도로 성장할 가능성이 높다"

아시아태평양 시장은 다수의 스타트업의 존재, 정부의 규제 완화, 바이오시밀러의 개발, 제조 및 상용화를 위한 대기업과 국내 기업 간의 협력 증가로 인해 예측 기간 동안 가장 빠르게 성장하는 지역 부문이 될 것으로 예상됩니다.

목차

제1장 서론

제2장 조사 방법

제3장 주요 요약

제4장 주요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
  • 성장 촉진요인
  • 성장 억제요인
  • 기회
  • 과제
• 밸류체인 분석
• 생태계·시장 맵
• Porter's Five Forces 분석
• 규제 상황
• 주요 회의와 이벤트(2023년)
• 주요 이해관계자와 구입 기준
• 특허 분석
• 파이프라인 분석
• 가격 분석
• 고객의 비지니스에 영향을 미치는 동향과 혼란

제6장 바이오시밀러 시장 : 약제 클래스별

• 서론
• 단클론항체
  • 인플릭시맙
  • 리툭시맙
  • 트라스투주맙
  • 아달리무맙
  • 기타 단클론항체
• 과립구집락자극인자
• 인슐린
• 에리스로포이에틴
• 재조합 인간성장호르몬(rhGH)
• 에타너셉트
• 폴리트로핀
• 테리파라타이드
• 인터페론
• 항응고제
• 기타 약제 클래스

제7장 바이오시밀러 시장 : 적응증별

• 서론
• 종양
• 염증성 질환·자가면역질환
• 만성질환
• 혈액질환
• 성장호르몬결핍증
• 감염증
• 기타 적응증

제8장 바이오시밀러 시장 : 지역별

• 서론
• 유럽
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타 유럽
• 아시아태평양
  • 중국
  • 한국
  • 인도
  • 일본
  • 호주
  • 기타 아시아태평양
• 북미
  • 미국
  • 캐나다
• 라틴아메리카
• 중동 및 아프리카

제9장 경쟁 상황

• 서론
• 주요 기업이 채용한 전략
• 매출 점유율 분석
• 시장 점유율 분석
• 기업 평가 쿼드런트(2022년)
• 상위 기업 30개사 경쟁 벤치마킹
• 신흥 기업/중소기업용 기업 평가 쿼드런트(2022년)
• 신흥 기업/중소기업 경쟁 벤치마킹
• 경쟁 시나리오와 동향

제10장 기업 개요

• 주요 기업
  • NOVARTIS AG
  • PFIZER INC.
  • AMGEN INC.
  • DR. REDDY'S LABORATORIES LTD.
  • ELI LILLY AND COMPANY
  • TEVA PHARMACEUTICAL INDUSTRIES
  • FRESENIUS KABI AG
  • STADA ARZNEIMITTEL AG
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • F. HOFFMANN-LA ROCHE LTD
  • CELLTRION HEALTHCARE CO., LTD.
  • SAMSUNG BIOLOGICS
  • COHERUS BIOSCIENCES
  • BIOCON
  • AMEGA BIOTECH
  • APOTEX INC.
  • BIOCAD
  • MABXIENCE
  • PROBIOMED
  • FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
  • INTAS PHARMACEUTICALS LTD.
  • RELIANCE LIFE SCIENCES
  • KASHIV BIOSCIENCES, LLC
  • USV PRIVATE LIMITED
  • AMNEAL PHARMACEUTICALS, INC.
• 기타 기업
  • FORMYCON AG
  • POLPHARMA BIOLOGICS GROUP
  • AMPHASTAR PHARMACEUTICALS, INC.
  • ALVOTECH
  • UCB SA

제11장 부록

ksm

영문 목차

영문목차

The global biosimilars market size is projected to reach USD 66.9 billion by 2028 from USD 29.4 billion in 2023, at a CAGR of 17.8% during the forecast period. Factors such as regulatory approvals, favorable reimbursement policies, rising demand for cost effective biosimilars is driving the market growth.

"The monoclonal antibodies product segment accounted for the highest growth rate in the biosimilars market, by drug class, during the forecast period"

In 2022, the monoclonal antibodies product segment accounted for the largest share of the biosimilars market, mainly due to the low prices of biosimilar monoclonal antibodies compared to the reference drugs and increased adoption of labs in the the treatment of cancer, autoimmune disorders, and osteoporosis. The growth of the fastest-growing segment was attributed to the rising incidence of cancer and chronic diseases globally. Increased approval for interchangeability insulin is likely to have positive impact on market.

"Oncology segment accounted for the largest share of the indication segment in 2022."

Based on the indication, the biosimilars market is segmented into oncology, inflammatory and autoimmune diseases, chronic diseases, blood disorders, growth hormone deficiency, infectious diseases, and other indications. Rising demand for cancer drugs, growth hormones across various regions is propelling the growth of the market.

"Asia Pacific region is likely to grow at a faster pace."

The biosimilars market is segmented into Europe, Asia Pacific, North America, latin America and Middle East and Africa. The APAC market is expected to be the fastest-growing regional segment during the forecast period due to the presence of numerous emerging players, less-stringent government regulations, and increasing cooperation among leading and regional players for development, manufacturing and commercialization of biosimilars.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70%, and Demand Side - 30%
• By Designation (Supply Side): Managers - 45%, CXOs & Directors - 30%, Executives- 25%
• By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

Lists of Companies Profiled in the Report:

• Novartis AG (Switzerland)
• Pfizer Inc. (US)
• Dr. Reddy's Laboratories Ltd. (India)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Eli Lilly & Company (US)
• Amgen Inc. (US)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Samsung Biologics (South Korea)
• Fresenius SE & Co. KGaA (Germany)
• Boehringer Ingelheim International GmbH. (Germany)
• STADA Arzneimittel AG (Germany)
• Coherus BioSciences (US)
• FUJIFILM Kyova Kirin Biologics Co., Ltd. (Japan)
• USV Limited (India),
• Amneal Pharmaceuticals LLC. (US)
• Celltrion Healthcare (South Korea)
• Biocon (India)
• Intas Pharmaceuticals Ltd. (India)
• Reliance Life Sciences (India)
• AMEGA Biotech (Argentina)
• Apotex, Inc. (Canada)
• BIOCAD (Russia)
• mAbxience (Spain)
• Probiomed (Mexico)
• Kashiv BioSciences, LLC (US),
• Formycon AG (Germany)
• Polpharma Biologics Group (Poland)
• Amphastar Pharmaceuticals, Inc. (US)
• Alvotech (Iceland)
• UCB SA, (Belgium)

Research Coverage:

This report provides a detailed picture of the biosimilars market. It aims at estimating the size and future growth potential of the market across different segments, such as drug class, indication and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall biosimilars market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing demand for biosimilars, launch of novel biosimilars, rising geriatric population & chronic disease incidence, abbreviated regulatory process & interchangeability), restraints (complexities in manufacturing), opportunities (emerging markets, patent expiry of blockbuster biologics and research on new indication), and challenges (excess competition & regulatory challenges) influencing the growth of biosimilars market.
• Product Development/Innovation: Detailed insights on newly launched products, and pipeline analysis of the biosimilars market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the biosimilars market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the biosimilars market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Novartis AG (Switzerland), Pfizer Inc. (US), Dr. Reddy's Laboratories Ltd. (India), F. Hoffmann-La Roche Ltd (Switzerland), Eli Lilly & Company (US), Amgen Inc. (US) and among others in the biosimilars market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 MARKET SCOPE
  • FIGURE 1 BIOSIMILARS MARKET SEGMENTATION
  • 1.3.1 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 LIMITATIONS
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES
• 1.8 RECESSION IMPACT

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • FIGURE 2 RESEARCH DESIGN
  • 2.1.1 SECONDARY DATA
  • 2.1.2 PRIMARY DATA
  • FIGURE 3 BIOSIMILARS MARKET: BREAKDOWN OF PRIMARIES
• 2.2 MARKET SIZE ESTIMATION
  • FIGURE 4 BIOSIMILARS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022
  • FIGURE 5 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022
  • FIGURE 6 ILLUSTRATIVE EXAMPLE OF REVENUE SHARE ANALYSIS AND SEGMENTAL ANALYSIS, 2022
  • FIGURE 7 ILLUSTRATIVE EXAMPLE OF REVENUE SHARE FOR DRUG CLASS & INDICATION, 2022
  • 2.2.1 INSIGHTS FROM PRIMARIES
  • FIGURE 8 MARKET VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 9 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• 2.3 GROWTH RATE ASSUMPTIONS
  • FIGURE 10 BIOSIMILARS MARKET: CAGR PROJECTIONS, 2023-2028
  • FIGURE 11 BIOSIMILARS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, CHALLENGES, AND OPPORTUNITIES
• 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION
  • FIGURE 12 DATA TRIANGULATION METHODOLOGY
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RISK ANALYSIS
• 2.7 BIOSIMILARS MARKET: RECESSION IMPACT ANALYSIS
  • TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024-2027 (% GROWTH)
  • TABLE 2 US HEALTH EXPENDITURE, 2019-2027 (USD MILLION)
  • TABLE 3 US HEALTH EXPENDITURE, 2023-2027 (USD MILLION)

3 EXECUTIVE SUMMARY

• FIGURE 13 BIOSIMILARS MARKET, BY DRUG CLASS, 2023 VS. 2028 (USD MILLION)
• FIGURE 14 BIOSIMILARS MARKET, BY INDICATION, 2023 VS. 2028 (USD MILLION)
• FIGURE 15 BIOSIMILARS MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)

4 PREMIUM INSIGHTS

• 4.1 BIOSIMILARS MARKET OVERVIEW
  • FIGURE 16 RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE MARKET GROWTH
• 4.2 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS AND COUNTRY (2022)
  • FIGURE 17 MONOCLONAL ANTIBODIES AND US TO DOMINATE NORTH AMERICAN MARKET
• 4.3 BIOSIMILARS MARKET: GEOGRAPHICAL SNAPSHOT
  • FIGURE 18 ASIA PACIFIC TO REGISTER HIGHEST GROWTH OVER FORECAST PERIOD

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • FIGURE 19 BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • TABLE 4 BIOSIMILARS MARKET: IMPACT ANALYSIS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing demand for biosimilars
    • 5.2.1.2 Launch of novel biosimilars
  • FIGURE 20 US: NUMBER OF APPROVED AND LAUNCHED BIOSIMILARS, 2015 TO 2022
    • 5.2.1.3 Rising geriatric population and chronic disease incidence
  • FIGURE 21 GERIATRIC POPULATION, BY REGION, 2020 VS. 2030 VS. 2050 (MILLION)
  • FIGURE 22 ESTIMATED NUMBER OF NEW CANCER CASES FROM 2020 TO 2030
  • FIGURE 23 INCIDENCE OF DIABETES, BY REGION, 2019 VS. 2030 VS. 2045 (MILLION)
    • 5.2.1.4 Abbreviated regulatory approval process and interchangeability
  • TABLE 5 APPROVED BIOSIMILARS WITH INTERCHANGEABLE DESIGNATION
  • FIGURE 24 COMPARISON OF REFERENCE PRODUCTS, BIOSIMILARS, AND INTERCHANGEABLE PRODUCTS
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Complexities in manufacturing
  • TABLE 6 COMPARISON OF DRUG DEVELOPMENT PROCESSES, BY TYPE
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Emerging markets
    • 5.2.3.2 Patent expiries of blockbuster biologics and research into new indications
  • TABLE 7 LIST OF KEY BIOLOGICS FACING PATENT EXPIRY
  • 5.2.4 CHALLENGES
    • 5.2.4.1 High competition and regulatory challenges
• 5.3 VALUE CHAIN ANALYSIS
  • FIGURE 25 VALUE CHAIN ANALYSIS FOR BIOSIMILARS
• 5.4 ECOSYSTEM MARKET MAP
  • FIGURE 26 ECOSYSTEM MARKET MAP FOR BIOSIMILARS
• 5.5 PORTER'S FIVE FORCES ANALYSIS
  • TABLE 8 BIOSIMILARS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • 5.5.1 THREAT OF NEW ENTRANTS
  • 5.5.2 THREAT OF SUBSTITUTES
  • 5.5.3 BARGAINING POWER OF SUPPLIERS
  • 5.5.4 BARGAINING POWER OF BUYERS
  • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.6 REGULATORY LANDSCAPE
  • TABLE 9 BIOSIMILARS MARKET: REGULATORY LANDSCAPE
  • TABLE 10 REGULATORY BODIES, GOVERNMENT AGENCIES & OTHER ORGANIZATIONS
  • TABLE 11 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 ROW: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.7 KEY CONFERENCES AND EVENTS, 2023
  • TABLE 15 BIOSIMILARS MARKET: DETAILED LIST OF CONFERENCES & EVENTS, 2023
• 5.8 KEY STAKEHOLDERS AND BUYING CRITERIA
  • FIGURE 27 KEY STAKEHOLDERS IN BUYING PROCESS
  • FIGURE 28 INFLUENCE OF END USERS ON BUYING PROCESS
• 5.9 PATENT ANALYSIS
• 5.10 PIPELINE ANALYSIS
• 5.11 PRICING ANALYSIS
  • TABLE 16 BIOSIMILAR PRICE, BY INDICATION AND REGION
• 5.12 TRENDS AND DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES

6 BIOSIMILARS MARKET, BY DRUG CLASS

• 6.1 INTRODUCTION
  • TABLE 17 BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
• 6.2 MONOCLONAL ANTIBODIES
  • TABLE 18 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 19 BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 20 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 21 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 22 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.2.1 INFLIXIMAB
    • 6.2.1.1 Infliximab to dominate mAbs market
  • TABLE 23 BIOSIMILARS MARKET FOR INFLIXIMAB, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 24 NORTH AMERICA: BIOSIMILARS MARKET FOR INFLIXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 25 EUROPE: BIOSIMILARS MARKET FOR INFLIXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 26 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFLIXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.2.2 RITUXIMAB
    • 6.2.2.1 Rising incidences of autoimmune diseases and cancer to boost market growth
  • TABLE 27 BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 28 NORTH AMERICA: BIOSIMILARS MARKET FOR RITUXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 29 EUROPE: BIOSIMILARS MARKET FOR RITUXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: BIOSIMILARS MARKET FOR RITUXIMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.2.3 TRASTUZUMAB
    • 6.2.3.1 Increasing breast cancer prevalence to drive market growth
  • TABLE 31 BIOSIMILARS MARKET FOR TRASTUZUMAB, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 32 NORTH AMERICA: BIOSIMILARS MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 33 EUROPE: BIOSIMILARS MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 34 ASIA PACIFIC: BIOSIMILARS MARKET FOR TRASTUZUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.2.4 ADALIMUMAB
    • 6.2.4.1 Loss of patent exclusivity to drive research
  • TABLE 35 FDA APPROVAL AND EU LAUNCH STATUS OF BIOSIMILARS TO HUMIRA
  • TABLE 36 BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 37 NORTH AMERICA: BIOSIMILARS MARKET FOR ADALIMUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 38 EUROPE: BIOSIMILARS MARKET FOR ADALIMUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: BIOSIMILARS MARKET FOR ADALIMUMAB, BY COUNTRY, 2021-2028 (USD MILLION)
  • 6.2.5 OTHER MONOCLONAL ANTIBODIES
  • TABLE 40 BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 41 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 42 EUROPE: BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.3 GRANULOCYTE COLONY-STIMULATING FACTOR
  • 6.3.1 LAUNCH OF BIOSIMILARS TO PROMOTE MARKET GROWTH
  • TABLE 44 LIST OF APPROVED BIOSIMILARS FOR G-CSF
  • TABLE 45 BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 46 NORTH AMERICA: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 47 EUROPE: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 48 ASIA PACIFIC: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.4 INSULIN
  • 6.4.1 INCREASING INCIDENCE OF DIABETES TO DRIVE MARKET
  • TABLE 49 BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 50 NORTH AMERICA: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 51 EUROPE: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 52 ASIA PACIFIC: BIOSIMILARS MARKET FOR INSULIN, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.5 ERYTHROPOIETIN
  • 6.5.1 RISING INCIDENCE OF BLOOD DISORDERS TO AUGMENT MARKET GROWTH
  • TABLE 53 LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
  • TABLE 54 BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 55 NORTH AMERICA: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 56 EUROPE: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.6 RECOMBINANT HUMAN GROWTH HORMONE
  • 6.6.1 INCREASING INCIDENCE OF GROWTH DEFICIENCY DISORDERS TO PROPEL MARKET
  • TABLE 58 BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 59 NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 60 EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 61 ASIA PACIFIC: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.7 ETANERCEPT
  • 6.7.1 APAC TO WITNESS HIGHEST GROWTH IN ETANERCEPT MARKET
  • TABLE 62 BIOSIMILARS MARKET FOR ETANERCEPT, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 63 NORTH AMERICA: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 64 EUROPE: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 65 ASIA PACIFIC: BIOSIMILARS MARKET FOR ETANERCEPT, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.8 FOLLITROPIN
  • 6.8.1 INCREASING APPLICATION OF FOLLITROPIN IN INFERTILITY TREATMENT TO DRIVE MARKET
  • TABLE 66 BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 67 NORTH AMERICA: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 68 EUROPE: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 69 ASIA PACIFIC: BIOSIMILARS MARKET FOR FOLLITROPIN, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.9 TERIPARATIDE
  • 6.9.1 INCREASING INCIDENCE OF OSTEOPOROSIS TO BOOST DEMAND
  • TABLE 70 BIOSIMILARS MARKET FOR TERIPARATIDE, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 71 NORTH AMERICA: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 72 EUROPE: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 73 ASIA PACIFIC: BIOSIMILARS MARKET FOR TERIPARATIDE, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.10 INTERFERONS
  • 6.10.1 RISING INCIDENCE OF INFECTIOUS DISEASES TO SUPPORT MARKET GROWTH
  • TABLE 74 BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: BIOSIMILARS MARKET FOR INTERFERONS, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.11 ANTICOAGULANTS
  • 6.11.1 WIDE RANGE OF APPLICATIONS TO DRIVE DEMAND FOR ENOXAPARIN SODIUM BIOSIMILARS
  • TABLE 76 BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 77 NORTH AMERICA: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 78 EUROPE: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 79 ASIA PACIFIC: BIOSIMILARS MARKET FOR ANTICOAGULANTS, BY COUNTRY, 2021-2028 (USD MILLION)
• 6.12 OTHER DRUG CLASSES
  • TABLE 80 BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER DRUG CLASSES, BY COUNTRY, 2021-2028 (USD MILLION)

7 BIOSIMILARS MARKET, BY INDICATION

• 7.1 INTRODUCTION
  • TABLE 82 BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
• 7.2 ONCOLOGY
  • 7.2.1 INCREASED APPROVALS AND LAUNCH OF BIOSIMILARS IN ONCOLOGY TO DRIVE MARKET
  • TABLE 83 BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 84 NORTH AMERICA: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 85 EUROPE: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: BIOSIMILARS MARKET FOR ONCOLOGY, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.3 INFLAMMATORY & AUTOIMMUNE DISEASES
  • 7.3.1 CHANGES IN LIFESTYLES AND ENVIRONMENTAL CONDITIONS TO INCREASE DISEASE INCIDENCE
  • TABLE 87 BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 88 NORTH AMERICA: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 89 EUROPE: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 90 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFLAMMATORY & AUTOIMMUNE DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.4 CHRONIC DISEASES
  • 7.4.1 HIGH BURDEN OF CVD AND DIABETES WORLDWIDE TO DRIVE MARKET GROWTH
  • TABLE 91 BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 92 NORTH AMERICA: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 93 EUROPE: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.5 BLOOD DISORDERS
  • 7.5.1 INCREASING INCIDENCE OF BLOOD DISORDERS TO BOOST BIOSIMILAR DEMAND
  • TABLE 95 BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 96 NORTH AMERICA: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 97 EUROPE: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.6 GROWTH HORMONE DEFICIENCY
  • 7.6.1 RISING USE OF BIOSIMILARS FOR TREATMENT TO SUPPORT MARKET GROWTH
  • TABLE 99 BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 100 NORTH AMERICA: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 101 EUROPE: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 102 ASIA PACIFIC: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.7 INFECTIOUS DISEASES
  • 7.7.1 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES TO GROW RAPIDLY IN ASIA PACIFIC
  • TABLE 103 BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2021-2028 (USD MILLION)
• 7.8 OTHER INDICATIONS
  • TABLE 105 BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY REGION, 2021-2028 (USD MILLION)
  • TABLE 106 NORTH AMERICA: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 107 EUROPE: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 108 ASIA PACIFIC: BIOSIMILARS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2021-2028 (USD MILLION)

8 BIOSIMILARS MARKET, BY REGION

• 8.1 INTRODUCTION
  • TABLE 109 BIOSIMILARS MARKET, BY REGION, 2021-2028 (USD MILLION)
• 8.2 EUROPE
  • TABLE 110 EUROPE: LIST OF APPROVED BIOSIMILARS
  • FIGURE 29 EUROPE: BIOSIMILARS MARKET SNAPSHOT
  • TABLE 111 EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 112 EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 113 EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 114 EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.2.1 GERMANY
    • 8.2.1.1 Germany to dominate European biosimilars market
  • TABLE 115 GERMANY: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 116 GERMANY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 117 GERMANY: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.2.2 UK
    • 8.2.2.1 Increasing adoption of biosimilars to boost market
  • TABLE 118 UK: LIST OF APPROVED BIOSIMILARS
  • TABLE 119 UK: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 120 UK: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 121 UK: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.2.3 FRANCE
    • 8.2.3.1 Rising geriatric population to drive market growth
  • TABLE 122 FRANCE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 123 FRANCE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 124 FRANCE: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.2.4 ITALY
    • 8.2.4.1 Favorable government policies to propel adoption of biosimilars
  • TABLE 125 ITALY: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 126 ITALY: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 127 ITALY: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.2.5 SPAIN
    • 8.2.5.1 Favorable patient incentives to promote biosimilar use
  • TABLE 128 SPAIN: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 129 SPAIN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 130 SPAIN: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.2.6 REST OF EUROPE
  • TABLE 131 REST OF EUROPE: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 132 REST OF EUROPE: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 133 REST OF EUROPE: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.2.7 EUROPE: RECESSION IMPACT
• 8.3 ASIA PACIFIC
  • FIGURE 30 ASIA PACIFIC: BIOSIMILARS MARKET SNAPSHOT
  • TABLE 134 ASIA PACIFIC: BIOSIMILARS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 135 ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 137 ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.3.1 CHINA
    • 8.3.1.1 China to register highest growth in Asia Pacific market
  • TABLE 138 BIOSIMILARS APPROVED IN CHINA
  • TABLE 139 CHINA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 140 CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 141 CHINA: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.3.2 SOUTH KOREA
    • 8.3.2.1 Favorable government initiatives to support growth
  • TABLE 142 SOUTH KOREA: LIST OF APPROVED BIOSIMILARS
  • TABLE 143 SOUTH KOREA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 144 SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 145 SOUTH KOREA: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.3.3 INDIA
    • 8.3.3.1 Increasing biosimilar launches and approvals to support market growth
  • TABLE 146 BIOSIMILARS APPROVED AND MARKETED IN INDIA
  • TABLE 147 INDIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 148 INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 149 INDIA: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.3.4 JAPAN
    • 8.3.4.1 Large geriatric population to drive market growth
  • TABLE 150 JAPAN: LIST OF APPROVED BIOSIMILARS
  • TABLE 151 JAPAN: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 152 JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 153 JAPAN: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.3.5 AUSTRALIA
    • 8.3.5.1 Favorable regulatory changes and increasing disease incidence to propel growth
  • TABLE 154 AUSTRALIA: LIST OF APPROVED BIOSIMILARS
  • TABLE 155 AUSTRALIA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 156 AUSTRALIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 157 AUSTRALIA: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.3.6 REST OF ASIA PACIFIC
  • TABLE 158 NEW ZEALAND: LIST OF APPROVED BIOSIMILARS
  • TABLE 159 MALAYSIA: LIST OF APPROVED BIOSIMILARS
  • TABLE 160 SINGAPORE: LIST OF APPROVED BIOSIMILARS
  • TABLE 161 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 162 REST OF ASIA PACIFIC: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 163 REST OF ASIA PACIFIC: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.3.7 ASIA PACIFIC: RECESSION IMPACT
• 8.4 NORTH AMERICA
  • TABLE 164 NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2021-2028 (USD MILLION)
  • TABLE 165 NORTH AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 166 NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 167 NORTH AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.4.1 US
    • 8.4.1.1 US to dominate North American biosimilars market
  • TABLE 168 US: LIST OF APPROVED BIOSIMILARS
  • TABLE 169 US: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 170 US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 171 US: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.4.2 CANADA
    • 8.4.2.1 Favorable government initiatives to support market
  • TABLE 172 CANADA: LIST OF APPROVED BIOSIMILARS
  • TABLE 173 CANADA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 174 CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 175 CANADA: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.4.3 NORTH AMERICA: RECESSION IMPACT
• 8.5 LATIN AMERICA
  • 8.5.1 RISING INCIDENCE OF CANCER TO DRIVE MARKET
  • TABLE 176 LATIN AMERICA: LIST OF APPROVED BIOSIMILARS
  • TABLE 177 LATIN AMERICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 178 LATIN AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 179 LATIN AMERICA: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.5.2 LATIN AMERICA: RECESSION IMPACT
• 8.6 MIDDLE EAST AND AFRICA
  • 8.6.1 FAVORABLE REGULATORY REFORMS AND INFRASTRUCTURAL DEVELOPMENT TO FAVOR MARKET GROWTH
  • TABLE 180 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY DRUG CLASS, 2021-2028 (USD MILLION)
  • TABLE 181 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2021-2028 (USD MILLION)
  • TABLE 182 MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY INDICATION, 2021-2028 (USD MILLION)
  • 8.6.2 MIDDLE EAST AND AFRICA: RECESSION IMPACT

9 COMPETITIVE LANDSCAPE

• 9.1 INTRODUCTION
• 9.2 STRATEGIES ADOPTED BY KEY PLAYERS
  • FIGURE 31 BIOSIMILARS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
• 9.3 REVENUE SHARE ANALYSIS
  • FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS, 2020-2023
• 9.4 MARKET SHARE ANALYSIS
  • FIGURE 33 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022
  • TABLE 183 BIOSIMILARS MARKET: DEGREE OF COMPETITION
• 9.5 COMPANY EVALUATION QUADRANT, 2022
  • 9.5.1 STARS
  • 9.5.2 EMERGING LEADERS
  • 9.5.3 PERVASIVE PLAYERS
  • 9.5.4 PARTICIPANTS
  • FIGURE 34 BIOSIMILARS MARKET: COMPANY EVALUATION QUADRANT, 2022
• 9.6 COMPETITIVE BENCHMARKING OF TOP 30 PLAYERS
  • 9.6.1 COMPANY FOOTPRINT ANALYSIS (30 COMPANIES)
  • TABLE 184 BIOSIMILARS MARKET: COMPANY FOOTPRINT ANALYSIS
  • 9.6.2 PRODUCT FOOTPRINT ANALYSIS (30 COMPANIES)
  • TABLE 185 BIOSIMILARS MARKET: PRODUCT FOOTPRINT ANALYSIS
  • 9.6.3 REGIONAL FOOTPRINT ANALYSIS (30 COMPANIES)
  • TABLE 186 BIOSIMILARS MARKET: REGIONAL FOOTPRINT ANALYSIS
• 9.7 COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2022
  • 9.7.1 PROGRESSIVE COMPANIES
  • 9.7.2 STARTING BLOCKS
  • 9.7.3 RESPONSIVE COMPANIES
  • 9.7.4 DYNAMIC COMPANIES
  • FIGURE 35 BIOSIMILARS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022
• 9.8 COMPETITIVE BENCHMARKING OF START-UPS/SMES
  • TABLE 187 BIOSIMILARS MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 188 BIOSIMILARS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
• 9.9 COMPETITIVE SCENARIO AND TRENDS
  • 9.9.1 PRODUCT LAUNCHES & APPROVALS
  • TABLE 189 BIOSIMILARS MARKET: PRODUCT LAUNCHES, JANUARY 2020-APRIL 2023
  • 9.9.2 DEALS
  • TABLE 190 BIOSIMILARS MARKET: DEALS, JANUARY 2020-APRIL 2023
  • 9.9.3 OTHER DEVELOPMENTS
  • TABLE 191 BIOSIMILARS MARKET: OTHER DEVELOPMENTS, JANUARY 2020-APRIL 2023

10 COMPANY PROFILES

• 10.1 KEY MARKET PLAYERS
• (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))**
• 10.1.1 NOVARTIS AG
• TABLE 192 NOVARTIS AG: BUSINESS OVERVIEW
• FIGURE 36 NOVARTIS AG: COMPANY SNAPSHOT (2022)
• 10.1.2 PFIZER INC.
• TABLE 193 PFIZER INC.: BUSINESS OVERVIEW
• FIGURE 37 PFIZER INC.: COMPANY SNAPSHOT (2022)
• 10.1.3 AMGEN INC.
• TABLE 194 AMGEN INC.: BUSINESS OVERVIEW
• FIGURE 38 AMGEN INC.: COMPANY SNAPSHOT (2022)
• 10.1.4 DR. REDDY'S LABORATORIES LTD.
• TABLE 195 DR. REDDY'S LABORATORIES LTD.: BUSINESS OVERVIEW
• FIGURE 39 DR. REDDY'S LABORATORIES LTD.: COMPANY SNAPSHOT (2022)
• 10.1.5 ELI LILLY AND COMPANY
• TABLE 196 ELI LILLY AND COMPANY: BUSINESS OVERVIEW
• FIGURE 40 ELI LILLY AND COMPANY: COMPANY SNAPSHOT (2022)
• 10.1.6 TEVA PHARMACEUTICAL INDUSTRIES
• TABLE 197 TEVA PHARMACEUTICAL INDUSTRIES: BUSINESS OVERVIEW
• FIGURE 41 TEVA PHARMACEUTICAL INDUSTRIES: COMPANY SNAPSHOT (2022)
• 10.1.7 FRESENIUS KABI AG
• TABLE 198 FRESENIUS KABI AG: BUSINESS OVERVIEW
• FIGURE 42 FRESENIUS KABI AG: COMPANY SNAPSHOT (2022)
• 10.1.8 STADA ARZNEIMITTEL AG
• TABLE 199 STADA ARZNEIMITTEL AG: BUSINESS OVERVIEW
• FIGURE 43 STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT (2022)
• 10.1.9 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• TABLE 200 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: BUSINESS OVERVIEW
• FIGURE 44 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT (2022)
• 10.1.10 F. HOFFMANN-LA ROCHE LTD
• TABLE 201 F. HOFFMANN-LA ROCHE LTD: BUSINESS OVERVIEW
• FIGURE 45 F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT (2022)
• 10.1.11 CELLTRION HEALTHCARE CO., LTD.
• TABLE 202 CELLTRION HEALTHCARE CO., LTD.: BUSINESS OVERVIEW
• FIGURE 46 CELLTRION HEALTHCARE CO., LTD.: COMPANY SNAPSHOT (2022)
• 10.1.12 SAMSUNG BIOLOGICS
• TABLE 203 SAMSUNG BIOLOGICS: BUSINESS OVERVIEW
• FIGURE 47 SAMSUNG BIOLOGICS: COMPANY SNAPSHOT (2022)
• 10.1.13 COHERUS BIOSCIENCES
• TABLE 204 COHERUS BIOSCIENCES: BUSINESS OVERVIEW
• FIGURE 48 COHERUS BIOSCIENCES: COMPANY SNAPSHOT (2022)
• 10.1.14 BIOCON
• TABLE 205 BIOCON: BUSINESS OVERVIEW
• FIGURE 49 BIOCON: COMPANY SNAPSHOT (2022)
• 10.1.15 AMEGA BIOTECH
• TABLE 206 AMEGA BIOTECH: BUSINESS OVERVIEW
• 10.1.16 APOTEX INC.
• TABLE 207 APOTEX INC.: BUSINESS OVERVIEW
• 10.1.17 BIOCAD
• TABLE 208 BIOCAD: BUSINESS OVERVIEW
• 10.1.18 MABXIENCE
• TABLE 209 MABXIENCE: BUSINESS OVERVIEW
• 10.1.19 PROBIOMED
• TABLE 210 PROBIOMED: BUSINESS OVERVIEW
• 10.1.20 FUJIFILM KYOWA KIRIN BIOLOGICS CO., LTD.
• TABLE 211 FUJIFILM KYOVA KIRIN BIOLOGICS CO., LTD.: BUSINESS OVERVIEW
• 10.1.21 INTAS PHARMACEUTICALS LTD.
• TABLE 212 INTAS PHARMACEUTICALS LTD.: BUSINESS OVERVIEW
• 10.1.22 RELIANCE LIFE SCIENCES
• TABLE 213 RELIANCE LIFE SCIENCES: BUSINESS OVERVIEW
• 10.1.23 KASHIV BIOSCIENCES, LLC
• TABLE 214 KASHIV BIOSCIENCES, LLC: BUSINESS OVERVIEW
• 10.1.24 USV PRIVATE LIMITED
• TABLE 215 USV PRIVATE LIMITED: BUSINESS OVERVIEW
• 10.1.25 AMNEAL PHARMACEUTICALS, INC.
• TABLE 216 AMNEAL PHARMACEUTICALS INC.: BUSINESS OVERVIEW
• 10.2 OTHER PLAYERS
  • 10.2.1 FORMYCON AG
  • 10.2.2 POLPHARMA BIOLOGICS GROUP
  • 10.2.3 AMPHASTAR PHARMACEUTICALS, INC.
  • 10.2.4 ALVOTECH
  • 10.2.5 UCB SA
• *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX

• 11.1 DISCUSSION GUIDE
• 11.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 11.3 CUSTOMIZATION OPTIONS
• 11.4 RELATED REPORTS
• 11.5 AUTHOR DETAILS

관련자료